

NCI CTRP Attachment 3e

NCI CTRP Aggregate Accrual Portal Workflow and Screen Shots

Step 1: User accesses the NCI Clinical Trials Reporting Program Accrual website at <http://trials.nci.nih.gov/accrual> – see screenshot, page 2

Step 2: User enters “Username” and “Password” – see screenshot, page 2

Step 3: User reviews NCI Clinical Trials Reporting Program Accrual burden statement – see screenshot, page 3

Step 4: User selects to “Submit Aggregate Study Subject Accrual Information” and submits aggregate accrual information on a registered trial – see screenshot, pages 4 - 5



NCI CTRP Accrual



Welcome to NCI's Clinical Trials Reporting Program

This site allows for the upload of accrual data for trials submitted to CTRP. If trials are NCI-supported CTEP/DCP trials, accrual submission is handled via your normal accrual reporting, and it is not necessary to submit additional accrual data via this site. If you have any questions regarding accrual submission for a specific trial, please contact the Clinical Trials Reporting Office (CTRO) at ncictro@mail.nih.gov.

Want to learn more about the Reporting Program? Visit the [NCI Clinical Trials Reporting Program](#) website. You can email NCI CBIIT Application Support at ncicbiit@mail.nih.gov if you have questions or need assistance.

Sign In

Sign Up

Forgot Password

Username

Password

Sign In

Sub-CRRA Aggregate Study Subject Annual Information

NCI CLINICAL TRIALS REPORTING PROGRAM (CTRP) SYSTEM

This is a U.S. Government computer system, which may be accessed and used only for authorized Government business by authorized personnel. Unauthorized access or use of this computer system may subject violators to criminal, civil, and/or administrative action.

All information on this computer system may be intercepted, recorded, read, copied, and disclosed by and to authorized personnel for official purposes, including criminal investigations. Such information includes sensitive data encrypted to comply with confidentiality and privacy requirements. Access or use of this computer system by any person, whether authorized or unauthorized, constitutes consent to these terms. There is no right of privacy in this system.

NOTIFICATION TO RESPONDENT OF ESTIMATED BURDEN

OMB#: 0925-0600 EXP. DATE: 5/31/16

Public reporting burden for this collection of information is estimated to average fifteen (15) minutes for this questionnaire, including the time to review instructions, search existing data sources, gather and maintain the data needed, and complete and review the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a current, valid OMB control number.

Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden to

NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0600). Do not return the completed form to this address.

Accept

Reject

Trial Search

NCI Trial Identifier ?

ClinicalTrials.gov ID ?

Official Title ?

List of Trials

Show: 10

Search: Choose columns << < 1 > >>

NCI Trial Identifier	Official Title	Current Trial Status	Trial Type	Accrual Disease Terminology
NCI-2015-02030	A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC).	Active	Interventional	SDC

Showing 1 to 1 of 1

Export options: CSV | Excel



Trial Search

Batch Upload

Prior Submissions

Accrual Counts

Disease Search

Quick Links

Contact Us

Help

NCI-2015-02030: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC).

Lead Organization Trial ID: D419AC0001

Lead Organization: AstraZeneca Pharmaceuticals LP

Participating Site Subject Accrual Count

Message: Record Updated.

Show 10

Search: [input] << < 1 > >>

PO Id	Site Name	# of Subjects Enrolled	Date Last Updated	Actions
121010	Brigham and Women's Faulkner Hospital	12	02/03/2016 17:48	[Print] [Delete]

Showing 1 to 1 of 1

Reset

<< < 1 > >>